Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.60) by 16.67 percent. This is a 614.29 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $50.04 million which beat the analyst consensus estimate of $45.13 million by 10.87 percent. This is a 5.43 percent increase over sales of $47.46 million the same period last year.